|
Post by sportsrancho on Mar 20, 2018 13:00:18 GMT -5
3:20 On 3/20, hmm coincidence, I think not... If we close at $3.20, I'll buy you dinner! Seems to be some buzz going on over this one..
|
|
|
Post by awesomo on Mar 20, 2018 13:39:13 GMT -5
If we close at $3.20, I'll buy you dinner! Seems to be some buzz going on over this one.. Better be one hell of a speech to get this share price moving upwards in 40 minutes.
|
|
|
Post by buyitonsale on Mar 20, 2018 13:49:56 GMT -5
I heard that at 3:20 mark into the presentation Mike will reveal another clue about the upcoming recapitalization and RLS partnership.
|
|
|
Post by oldfishtowner on Mar 20, 2018 15:00:22 GMT -5
Great presentation by Mike C. Very up beat. Repeated several times with different stories that doctors can't believe the results with Afrezza. Just adds to the expectation that the ADA and the STAT study results will be a major turning point.
Dumped 25 sales reps who were not producing and subsequently filled most positions. 10 vacancies left. Might explain why scripts have not been growing as much as expected.
|
|
|
Post by lennymnkd on Mar 20, 2018 15:02:30 GMT -5
Cardiologist story was interesting...@ the end
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 20, 2018 15:02:51 GMT -5
Great presentation by Mike C. Very up beat. Repeated several times with different stories that doctors can't believe the results with Afrezza. Just adds to the expectation that the ADA and the STAT study results will be a major turning point. Dumped 25 sales reps who were not producing and subsequently filled most positions. 10 vacancies left. Might explain why scripts have not been growing as much as expected. Mike also said reps out of the field in meetings and Rx will start to increase again now that they are back selling. The nice thing about the STAT study is that the docs can try Afrezza with a few patients who have CGMs and then see for themselves how well it works. Docs are skeptical of reps and even of trial data since many have seen cooked information but CGM data provides a glaring truth and refutes the BS the docs will hear from competition.
|
|
|
Post by lakers on Mar 20, 2018 15:19:19 GMT -5
investors.mannkindcorp.com/static-files/e2aba247-3760-43ca-8312-10e46e8ee001Receptor Life Sciences Update: THC (Dronabinol): Target Product Profile CINV and appetite stimulation in AIDS Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting (CINV) : Past, Present, and Future Recommendations Correspondence: Karin Jordan, M.D., Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle/Wittenberg, Ernst-Grube-Str. 40, 06120 Halle/Saale, Germany. Telephone: 49-345-557-2924; Fax: 49-345-557-2950; e-mail: Karin.jordan@medizin.uni-halle.de Received March 19, 2007. Accepted July 9, 2007. theoncologist.alphamedpress.org/content/12/9/1143.longPalonosetron [Was listed as one of TS candidates by Mnkd] All three guidelines recommend palonosetron at a dose of 0.25 mg i.v. Oral palonosetron is not yet available. Palonosetron has a significantly longer half-life and a higher binding activity than the other 5-HT3RAs. The actual role of palonosetron in comparison with the other available 5-HT3RAs is discussed controversially in the guidelines. However, none of the three guidelines designates a preferred 5-HT3RA, although palonosetron outperformed ondansetron and dolasetron in some secondary endpoints in one study [13]. For a better understanding, the results of the three available randomized studies with palonosetron in the acute phase are outlined in Table 4. In a recently published meta-analysis, palonosetron was not included because only two studies were fully published at that time [12–14]. www.google.com/amp/s/dailytelescope.com/pr/chemotherapy-induced-nausea-and-vomiting-cinv-market-expected-to-reach-2659-million-globally-by-2022/90852/ampPortland, OR — 02/27/2018 — The Global Chemotherapy-Induced Nausea And Vomiting (CINV) Market was valued at $1,663 million in 2015, and is estimated to reach $2,659 million by 2022, registering a CAGR of 7.1% during the forecast period 2016-2022. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with breast, lung, and bronchus cancer. It is observed that approximately 35% of patients experienced nausea within 24 hours of chemotherapy, while 54% suffered from nausea and 34% experienced vomiting after 24 hours. Asia-Pacific is the fastest growing market at a CAGR of 9.8% owing to the increase in the cancer population and use of chemotherapeutic drugs. Aloxi and Zofran are the key CINV drugs with the largest share and boosting the growth of CINV market in Asia-Pacific during the forecast period 2016-2022. Other driving factors of CINV market in Asia-Pacific are increase in the healthcare spending and health infrastructure. The key players in the global chemotherapy-induced nausea and vomiting (CINV) drugs are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc James, BoD, former GSK CMO, knew GSK’s ZOFRAN and CINV well. www.mannkindcorp.com/about-us/board-of-directors/james-s-shannon/
|
|
|
Post by awesomo on Mar 20, 2018 16:10:54 GMT -5
Cardiologist story was interesting...@ the end Can you elaborate?
|
|
|
Post by lennymnkd on Mar 20, 2018 16:19:04 GMT -5
Cardio/ having issues with controll from surgery/ patient taking his her own controll ... and doctor being so impressed with afrezzas efficacy .. he needed to mention it to mike . Mike thought enough of it to mention it .
|
|
|
Post by mnholdem on Mar 20, 2018 18:37:59 GMT -5
Hillard Saveth. You'll find the post new the end of the Afrezza on Twitter II thread in the Blogs section. Sounds like he got the whole hospital asking about Afrezza!
|
|
|
Post by peppy on Mar 20, 2018 18:51:03 GMT -5
|
|
|
Post by sportsrancho on Mar 20, 2018 19:00:33 GMT -5
Hillard is a tireless advocate! The hospital is now going to adapt Afrezza. The head Endo was so impressed he met with Mike.
I don’t believe Hillard has met one doctor that has been aware Afrezza exists.
Why is that? They aren’t on Twitter..?. They never saw a SNY rep...?.. they haven’t gone to any conferences about what’s new in the diabetic field?
|
|
|
Post by peppy on Mar 20, 2018 19:13:13 GMT -5
Hillard is a tireless advocate! The hospital is now going to adapt Afrezza. The head Endo was so impressed he met with Mike. I don’t believe Hillard has met one doctor that has been aware Afrezza exists. Why is that? They aren’t on Twitter..?. They never saw a SNY rep...?.. they haven’t gone to any conferences about what’s new in the diabetic field? am going to listen to the cc replay to listen again what was said. Afrezza in the hospital would be very nice. Iatrogenic hyperglycemia all over the hospital.
|
|
|
Post by sportsrancho on Mar 20, 2018 19:13:56 GMT -5
I believe in my heart of hearts that this is the gut of the problem! They either don’t know about it, or they don’t understand it. Fix that and it’s lights on and off to the races:-)
|
|
|
Post by peppy on Mar 20, 2018 19:22:45 GMT -5
I believe in my heart of hearts that this is the gut of the problem! They either don’t know about it, or they don’t understand it. Fix that and it’s lights on and off to the races:-) what I think I did hear mike say, is the physicians couldn't believe the continuous glucose monitors. Now that they are allowed to see them. A physician can read the read out of the CGM in a moment. Mike said, " we see nothing slowing us down from this point forward" The STAT trial should do it. Anyone that wants afrezza from their physician walks in with the trial cgm data and HbA1c data. Once a physician starts to see good results; the theory is they add patients because the patients on afrezza will be happier.
|
|